{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:03:58Z","timestamp":1788264238384,"version":"build-2803163510"},"reference-count":39,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda (China) International Trading Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/13696998.2021.2020567","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T12:05:49Z","timestamp":1640001949000},"page":"99-107","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China"],"prefix":"10.1080","volume":"25","author":[{"given":"Jia","family":"Liu","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China"},{"name":"Center for Social Science Survey and Data, Tianjin University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[{"name":"Takeda China, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Hsiang","family":"Chuang","sequence":"additional","affiliation":[{"name":"Umea University, Umea, Sweden"},{"name":"GongJing Healthcare, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780049"},{"key":"e_1_3_3_3_1","unstructured":"The Global Cancer Observatory. China face sheet. Globanacan; 2020 [cited 2020 Oct 12]. Available from: http:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/160-china-fact-sheets.pdf"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-6-77"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.970542"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.0188"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Fanin R Ruiz De Elvira MC Sperotto A et\u00a0al. Autologous stem cell transplantation for T and null cell CD30-Positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). 1999;23:437\u2013442.","DOI":"10.1038\/sj.bmt.1701596"},{"key":"e_1_3_3_9_1","unstructured":"Takeda. RRcHL & RRsALCL expert\u2019s survey; 2019."},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2289"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_3_3_13_1","unstructured":"National Comprehensive Cancer Network. NCCN guidelines version 2.2015 peripheral T-cell lymphomas; 2015 [cited 2020 Jan 14]. Available from: https:\/\/www2.tri-kobe.org\/nccn\/guideline\/hematologic\/nhl\/english\/tcel.pdf"},{"key":"e_1_3_3_14_1","unstructured":"NICE. Technology appraisal guidance [TA478]: brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma; 2017."},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv201"},{"key":"e_1_3_3_16_1","volume-title":"China guidelines for pharmacoeconomic evaluations","author":"Liu G","year":"2020","unstructured":"Liu G, Hu S, Wu J, Wu J, Dong Z, Li H, eds. China guidelines for pharmacoeconomic evaluations. 2020th ed. Beijing: China Pharmaceutical Association; 2020.","edition":"2020"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxl030"},{"key":"e_1_3_3_18_1","first-page":"2097","article-title":"Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma","volume":"7","author":"Gutierrez A","year":"2014","unstructured":"Gutierrez A, Rodriguez J, Martinez-Serra J, et\u00a0al. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. Oncol Targets Ther. 2014;7:2097\u20132100.","journal-title":"Oncol Targets Ther"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1169"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0351-4"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg702"},{"key":"e_1_3_3_22_1","unstructured":"Yaozh website [cited 2020 Jan 14]. Available from: https:\/\/www.yaozh.com\/"},{"key":"e_1_3_3_23_1","unstructured":"Pricentric [cited 2020 Jan 14]. Available from: https:\/\/pricentric.alscg.com\/alspc"},{"key":"e_1_3_3_24_1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections; 2016 [cited 2020 Jan 14]. Available from: https:\/\/jnccn.org\/view\/journals\/jnccn\/14\/7\/article-p882.xml?ArticleBodyColorStyles=Inline%20PDF"},{"key":"e_1_3_3_25_1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: antiemesis; 2016 [cited 2020 Jan 14]. Available from: https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL; https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"key":"e_1_3_3_26_1","unstructured":"Beijing Social Security Network [cited 2020 Jan 28]. Available from: https:\/\/m.chashebao.com\/beijing\/yiliao\/17287.html"},{"key":"e_1_3_3_27_1","unstructured":"Kind P Hardman G Macran S. UK population norms for EQ-5D; 1999."},{"key":"e_1_3_3_28_1","unstructured":"National Bureau of Statistics of China. China statistic yearbook 2020 [cited 2020 Jun 28]. Available from: http:\/\/www.stats.gov.cn\/tjsj\/ndsj\/2020\/indexch.htm"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.36469\/9820"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.08.705"},{"key":"e_1_3_3_31_1","unstructured":"ClinicalTrials.gov. Brentuximab vedotin in Chinese participants with relapsed\/refractory CD30-positive hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL) [cited 2021 Jun 17]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02939014"},{"key":"e_1_3_3_32_1","volume-title":"Methods for the economic evaluation of health care programmes","author":"Drummond M","year":"1987","unstructured":"Drummond M, O\u2019Brien B, Stoddart G, et\u00a0al. Methods for the economic evaluation of health care programmes. 4th ed. New York: University Press; 1987.","edition":"4"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_3_3_34_1","volume-title":"Guidelines of Chinese Society of Clinical Oncology: lymphoid malignancies 2021","author":"Guidelines of Chinese Society of Clinical Oncology.","year":"2014","unstructured":"Guidelines of Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology: lymphoid malignancies 2021. Beijing: People\u2019s Republic Publisher; 2014."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2020.42400"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.2657.2657"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30818"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1542599"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00122"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.15.1453"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2021.2020567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:04:49Z","timestamp":1729163089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2021.2020567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/13696998.2021.2020567"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2021.2020567","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}